Apotea AB (publ)CHIX:APOTES 18 Return-on-Tangible-Equity is 37.75% as of Mar. 2026, which is 20% above its 10-year median of 31.41. GuruFocus rates CHIX:APOTES with a GF Score™ of 18/100. The stock has 1 warning sign investors should review. Among 580 Healthcare Providers & Services companies, Apotea AB (publ) ranks better than 77.41% on this metric.
Return-on-Tangible-Equity is calculated as Net Income divided by its average total shareholder tangible equity. Total shareholder tangible equity equals to Total Stockholders Equity minus Intangible Assets. Apotea AB (publ)'s annualized net income for the quarter that ended in Mar. 2026 was kr317 Mil. Apotea AB (publ)'s average shareholder tangible equity for the quarter that ended in Mar. 2026 was kr839 Mil. Therefore, Apotea AB (publ)'s annualized Return-on-Tangible-Equity for the quarter that ended in Mar. 2026 was 37.75%.
The historical rank and industry rank for Apotea AB (publ)'s Return-on-Tangible-Equity or its related term are showing as below:
CHIX:APOTEs'
s Return-on-Tangible-Equity Range Over the Past 10 Years
Min: 6.63 Med: 31.41 Max: 47.1
Current: 31
During the past 5 years, Apotea AB (publ)'s highest Return-on-Tangible-Equity was 47.10%. The lowest was 6.63%. And the median was 31.41%.
CHIX:APOTEs's Return-on-Tangible-Equity is ranked better than 77.41% of 580
companies
in the Healthcare Providers & Services industry
Industry Median: 10.065
vs CHIX:APOTEs: 31.00
Apotea AB (publ) (CHIX:APOTEs) Return-on-Tangible-Equity Explanation
Return-on-Tangible-Equity measures the rate of return on the ownership interest (shareholder's tangible equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' tangible equity (shareholders equity minus intangibles). Return-on-Tangible-Equity shows how well a company uses investment funds to generate earnings growth. Return-on-Tangible-Equitys between 15% and 20% are considered desirable.
Be Aware
Net Income is used.
Because a company can increase its Return-on-Tangible-Equity by having more financial leverage, it is important to watch the leverage ratio when investing in high Return-on-Tangible-Equity companies. Like Return-on-Tangible-Asset, Return-on-Tangible-Equity is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.
Asset light businesses require very few assets to generate very high earnings. Their Return-on-Tangible-Equitys can be extremely high.
Apotea AB (publ) Return-on-Tangible-Equity Related Terms
Apotea AB (publ) Return-on-Tangible-Equity Historical Data
* Premium members only.
The historical data trend for Apotea AB (publ)'s Return-on-Tangible-Equity can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Apotea AB (publ) Return-on-Tangible-Equity Competitor Comparison
For the Pharmaceutical Retailers subindustry, Apotea AB (publ)'s Return-on-Tangible-Equity, along with its competitors' market caps and Return-on-Tangible-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Apotea AB (publ) Return-on-Tangible-Equity vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, Apotea AB (publ)'s Return-on-Tangible-Equity distribution charts can be found below:
* The bar in red indicates where Apotea AB (publ)'s Return-on-Tangible-Equity falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Return-on-Tangible-Equity, the net income of the last fiscal year and the average total shareholder tangible equity over the fiscal year are used. In calculating the quarterly data,
the net income data used here is four times the quarterly (Mar. 2026) net income data.
Return-on-Tangible-Equity is displayed in the 10-year financial page.
What does a Return-on-Tangible-Equity of 37.75% mean?
Apotea AB (publ) (CHIX:APOTES) has a Return-on-Tangible-Equity of 37.75% as of Mar. 2026. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on Apotea AB (publ) and its competitors. This is 20% above median its historical median of 31.41. Over the past decade, Apotea AB (publ)'s Return-on-Tangible-Equity has ranged from 6.63 to 47.10. According to the industry distribution chart, Apotea AB (publ) ranks #131 out of 580 companies in the Healthcare Providers & Services industry, placing it in the top 22.6%.
Is Apotea AB (publ)'s Return-on-Tangible-Equity too high?
Apotea AB (publ)'s current Return-on-Tangible-Equity of 37.75% is 20% above median its 10-year median of 31.41. Over the past 10 years, this metric has ranged from a low of 6.63 to a high of 47.10. The Healthcare Providers & Services industry median Return-on-Tangible-Equity is 10.07. Apotea AB (publ)'s value of 37.75% is 275.1% above this industry median. Based on the distribution chart, Apotea AB (publ) ranks #131 out of 580 companies in the Healthcare Providers & Services industry, which is in the top quartile — a strong position relative to peers. Overall, Apotea AB (publ) has a GF Score™ of 18/100, reflecting its overall financial health beyond just this single metric.
How does Apotea AB (publ)'s Return-on-Tangible-Equity compare to competitors?
According to the Healthcare Providers & Services industry distribution chart, Apotea AB (publ) ranks #131 out of 580 companies for Return-on-Tangible-Equity. This places Apotea AB (publ) in the top 23% of its industry — outperforming the majority of peers. The industry median Return-on-Tangible-Equity is 10.07. Apotea AB (publ)'s value of 37.75% is 275.1% above this benchmark. Historically, Apotea AB (publ)'s own Return-on-Tangible-Equity has ranged from 6.63 to 47.10 over the past decade. While the company's 10-year median is 31.41 vs. the industry median of 10.07, Apotea AB (publ) has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Return-on-Tangible-Equity for a Healthcare Providers & Services company?
The median Return-on-Tangible-Equity among Healthcare Providers & Services companies is 10.07, based on 580 companies in the industry. Companies in the top quartile (top 25%) have a Return-on-Tangible-Equity significantly above this median, while those in the bottom quartile fall well below. However, Return-on-Tangible-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Apotea AB (publ)'s current Return-on-Tangible-Equity of 37.75% is 275.1% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Return-on-Tangible-Equity mean?
A high Return-on-Tangible-Equity can signal that a stock is expensive relative to its fundamentals. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on Apotea AB (publ) and its competitors. For the Healthcare Providers & Services industry, the median Return-on-Tangible-Equity is 10.07 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Apotea AB (publ)'s current Return-on-Tangible-Equity is 37.75%, which is 20% above median its own 10-year median of 31.41. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Apotea AB (publ) stock overvalued right now?
Apotea AB (publ) (CHIX:APOTES) has a current Return-on-Tangible-Equity of 37.75%. The current Return-on-Tangible-Equity is 37.75%, which is 20% above median its 10-year median of 31.41 and 275.1% above the Healthcare Providers & Services industry median of 10.07. Apotea AB (publ)'s overall GF Score™ is 18/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Return-on-Tangible-Equity calculated?
Return-on-Tangible-Equity is calculated from a company's financial statements. For Apotea AB (publ) (CHIX:APOTES), the current Return-on-Tangible-Equity is 37.75% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Apotea AB (publ) is engaged in the online pharmacy with fast deliveries, good prices and a large selection. Its vision is to be tomorrow's pharmacy by constantly facilitating and simplifying for the customer.
18GF Score
Get the complete analysis for CHIX:APOTES
Return-on-Tangible-Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CHIX:APOTES has been successfully added to your 
